Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. reported an insider stock transaction by its Chief Commercial Officer. On December 15, 2025, the officer acquired 1,402 shares of common stock at $0 when a portion of a restricted stock unit (RSU) award vested. On the same date, 594 shares were withheld and disposed of at $102.67 per share to cover tax withholding obligations, as explained in the footnotes.
After these transactions, the officer directly owned 26,795 shares of Guardant Health common stock. The RSU award was originally granted on June 9, 2023; 33% vested on June 15, 2024, and the remaining 67% is scheduled to vest in equal quarterly installments over the following two years. Following the reported transaction, 2,804 restricted stock units remained beneficially owned.
Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported open-market sales of company stock. On 12/15/2025, he sold 83,945 shares of common stock at a weighted average price of $103.8012 per share, and an additional 6,620 shares at a weighted average price of $104.0224 per share. Both transactions are coded as sales. Following these trades, he beneficially owns 2,047,143 shares of Guardant Health common stock directly. The prices reflect multiple individual transactions within narrow price ranges, and detailed trade breakdowns are available upon request from the company or the reporting person.
Guardant Health, Inc. reported an insider equity transaction by its Chief Medical Officer, Craig Eagle. On 12/15/2025, 1,402 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of previously granted restricted stock units. On the same date, 711 shares were disposed of at $102.67 per share, retained by the company to cover tax withholding obligations related to this vesting.
Following these transactions, Craig Eagle beneficially owned 45,007 shares of Guardant Health common stock directly, and held 2,804 restricted stock units as derivative securities. The underlying restricted stock unit award was granted on June 9, 2023 and vests over a three-year period, with 33% having vested on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. (GH) Chief Technology Officer Darya Chudova sold 5,451 shares of common stock on 12/15/2025 at a weighted average price of $104.0418 per share. The sale was executed through multiple transactions at prices ranging from $104.0401 to $104.0900. Following this transaction, Chudova beneficially owns 7,012 shares of Guardant Health common stock in direct ownership.
Guardant Health, Inc.'s Chief Financial Officer, Michael Brian Bell, reported equity transactions involving restricted stock units and common stock. On 12/15/2025, 1,233 and 2,039 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common shares. On the same date, 1,659 shares of common stock were withheld and disposed of at $102.67 per share to satisfy tax withholding obligations related to the vesting, with the filing stating that the amount retained was not in excess of the tax liability. After these transactions, he directly beneficially owned 29,665 shares of common stock and held 4,078 restricted stock units that continue to vest over multi‑year schedules.
Guardant Health, Inc. reported insider equity transactions by its Chief Technology Officer, Darya Chudova, on Form 4. On 12/08/2025, 68,144 shares of common stock were transferred at no cost from her direct ownership to the Chudova Family Trust, changing the form of ownership from direct to indirect. The filing also shows two open-market sales of Guardant Health common stock on the same date: 9,271 shares sold at a weighted average price of $106.0029 per share and 13,664 shares sold at a weighted average price of $105.0371 per share, executed in multiple transactions within narrow price ranges.
After these transactions, Chudova reported beneficial ownership of 21,734 shares held directly and 54,480 shares held indirectly through the Chudova Family Trust. The disclosure notes that 488 of the shares in Table I were previously acquired under Guardant Health's Employee Stock Purchase Plan.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported a series of open-market sales of the company’s common stock on December 5, 2025. The Form 4 shows multiple sale transactions at weighted average prices including $101.4027, $102.0946, $103.2528, $103.9717, $105.9863 and $106.7081 per share, with each line representing shares sold across narrower intraday price ranges from $100.710 up to $106.990 per share. Each transaction is coded as a sale and reported as directly held. Following these sales, Freeman’s directly owned position in Guardant Health common stock is disclosed as 25,987 shares.
Guardant Health (GH) director Roberto A. Mignone reported an equity transaction involving restricted stock units and common stock. On 11/21/2025, 264 restricted stock units were converted into 264 shares of common stock at an exercise price of $0, reported under transaction code M.
Following this transaction, Mignone beneficially owned 3,431 shares of Guardant Health common stock directly and 9,240 restricted stock units. The RSU award was granted on November 8, 2024 and vests over four years: 25% of the shares vested on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director reports small stock sale
A director of Guardant Health, Inc., identified in the signature as Musa Tariq, reported selling 116 shares of the company’s common stock on 11/19/2025. The sale, coded as an "S" transaction, was executed at a price of $96.25 per share. After this transaction, the reporting person beneficially owns 7,859 shares of Guardant Health common stock, held in direct ownership.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported an equity award vesting and share issuance. On 11/17/2025, 232 restricted stock units converted into 232 shares of common stock at an exercise price of $0, increasing his directly held common stock to 1,047 shares.
The transaction reflects ongoing vesting from a restricted stock unit grant awarded on July 17, 2024. That grant vests over four years, with 25% of the shares vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting in equal monthly installments over the following three years. After this conversion, he continues to hold 7,425 restricted stock units directly.